Novo Nordisk (NVO) said Thursday that the European Medicines Agency has approved an update to the Wegovy injection's product information, allowing it to be delivered to patients at a controlled temperature of up to 30 degrees Celsius for up to 48 hours.
Previously, the injection had to be kept cold for the entirety of the distribution and delivery process, from where it was made to where it will be used, the company said.
The reduced dependence on cold chain transport is expected to reduce packaging volume and weight as well as potentially lower delivery costs for pharmacies and online partners, Novo Nordisk said.
Shares of Novo Nordisk were down more than 1% in premarket activity Thursday.
Comments